Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

[1]  B. Pégourié,et al.  Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Hose,et al.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. , 2012, Blood.

[3]  J. Soulier,et al.  Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire , 2011, Haematologica.

[4]  H. Goldschmidt,et al.  Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Shaughnessy,et al.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. , 2011, Blood.

[6]  A. Órfão,et al.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Moreau,et al.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Kröger,et al.  Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. , 2010, Blood.

[9]  M. Boccadoro,et al.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Goldschmidt,et al.  Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT. , 2009 .

[11]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[12]  B. Barlogie,et al.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. , 2009, Blood.

[13]  N. Kröger,et al.  Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. , 2009, Experimental hematology.

[14]  I. Yakoub-Agha,et al.  Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. , 2008, Blood.

[15]  J. S. San Miguel,et al.  A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.

[16]  N. Kröger,et al.  Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques , 2008, Bone Marrow Transplantation.

[17]  J. San Miguel,et al.  Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma , 2008, Leukemia.

[18]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[19]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[20]  N. Kröger,et al.  Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. , 2006, Experimental hematology.

[21]  J. Bourhis,et al.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.

[22]  V. Callea,et al.  Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. , 2005, Leukemia research.

[23]  N. Kröger,et al.  Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. , 2004, Blood.

[24]  H. Einsele,et al.  Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. , 2004, Blood.

[25]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[26]  M. Boccadoro,et al.  Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. , 2003, Blood.

[27]  N. Kröger,et al.  Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. , 2002, Journal of hematotherapy & stem cell research.

[28]  N. Schmitz,et al.  Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. , 2002, Blood.

[29]  N. Kröger,et al.  Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.

[30]  M. Bernard,et al.  Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. , 2002, Blood.

[31]  N. Kröger,et al.  Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. , 2001, Journal of hematotherapy & stem cell research.

[32]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[33]  G. Martinelli,et al.  Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. San-Miguel,et al.  Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients , 2000, British journal of haematology.

[35]  A. Palumbo,et al.  Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[37]  M. Gobbi,et al.  [Allogeneic bone marrow transplantation in multiple myeloma]. , 1991, Haematologica.